Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Frontiers in Immunology|June 7, 2024
Drug survival superiority of tumor necrosis factor inhibitors and interleukin-17 inhibitors over Janus kinase inhibitors and interleukin-12/23 inhibitors in German psoriatic arthritis outpatients: retrospective analysis of the RHADAR databasePatrick-Pascal Strunz, Matthias Englbrecht, Linus Maximilian Risser, et al.
Arthritis Care & Research|August 3, 2016
Validation of Standardized Questionnaires Evaluating Symptoms of Depression in Rheumatoid Arthritis Patients: Approaches to Screening for a Frequent Yet Underrated ChallengeMatthias Englbrecht, Rieke Alten, Martin Aringer, et al.
Rheumatology International|August 13, 2024
Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients - a retrospective analysis from the RHADAR networkPatrick-Pascal Strunz, Matthias Englbrecht, Linus Maximilian Risser, et al.
Annals of the Rheumatic Diseases|May 7, 2021
SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseasesDavid Simon, Koray Tascilar, Filippo Fagni, et al.
Journal of Medical Internet Research|July 23, 2024
Diagnostic Accuracy of a Mobile AI-Based Symptom Checker and a Web-Based Self-Referral Tool in Rheumatology: Multicenter Randomized Controlled TrialJohannes Knitza, Koray Tascilar, Franziska Fuchs, et al.
Annals of the Rheumatic Diseases|February 10, 2015
Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO studyJudith Haschka, Matthias Englbrecht, Axel J Hueber, et al.
Arthritis Research & Therapy|April 14, 2021
Accuracy, patient-perceived usability, and acceptance of two symptom checkers (Ada and Rheport) in rheumatology: interim results from a randomized controlled crossover trialJohannes Knitza, Jacob Mohn, Christina Bergmann, et al.
The Journal of Rheumatology|December 4, 2018
Cost-effective Tapering Algorithm in Patients with Rheumatoid Arthritis: Combination of Multibiomarker Disease Activity Score and Autoantibody StatusMelanie Hagen, Matthias Englbrecht, Judith Haschka, et al.
Annals of the Rheumatic Diseases|October 21, 2015
Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatmentJuergen Rech, Axel J Hueber, Stephanie Finzel, et al.
Annals of the Rheumatic Diseases|June 22, 2016
Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugsCamille P Figueiredo, Holger Bang, Jayme Fogagnolo Cobra, et al.
Pageof 5